Objective: To understand the frequency of electrographic and clinical seizures in patients with stroke-like migraine attacks after radiation therapy (SMART), and determine whether SMART warrants comprehensive electroencephalographic (EEG) monitoring and aggressive seizure management. Methods: We searched our magnetic resonance brain imaging report database for all patients between
| INTRODUCTION
Delayed reversible symptoms after brain radiation therapy have been described in the so-called SMART syndrome (stroke-like migraine attacks after radiation therapy). In reported cases thus far, typical symptoms are prolonged unilateral migraines, hemispheric deficits including aphasia, hemiplegia, and seizures. 1 Characteristic magnetic resonance imaging (MRI) findings include prolonged but reversible gyriform cortical edema and enhancement.
2,3
The pathophysiology of SMART remains an active area of investigation, with several proposed mechanisms. One potential mechanism describes radiation-induced vascular dysfunction secondary to endothelial cell injury leading to an abnormal autoregulatory state. [2] [3] [4] Alternatively, neuronal dysfunction resulting from a reduced threshold to cortical spreading depression in SMART patients has been suggested. 3, 5 We propose that frequent electrographic seizure activity may be one mechanism causing similar prolonged reversible clinical symptoms and MRI findings.
Although seizures are recognized in SMART, they have not been well characterized. One review of published cases found a prevalence of 63.8% (N = 24). 6 Clinical status epilepticus (SE) has been recently recognized in a few isolated cases 7, 8 ; however, prolonged electroencephalographic (EEG) monitoring was not performed and quantification of EEG seizure activity in these patients remains unknown. At our institution, all patients with unexplained focal cortical deficits and mental status change, including patients with suspected SMART, undergo prolonged video EEG monitoring. This study systemically investigated the frequency of clinical and electrographic seizures of patients with SMART. We aim to determine whether SMART can be considered a clinical manifestation of frequent electrographic seizures or SE warranting comprehensive monitoring and timely seizure management.
| MATERIALS AND METHODS

| Patients and investigations
A database search of all brain MRIs at a single tertiary referral center between January 2013 and December 2015 was performed containing search items "stroke-like migraine after radiation therapy," "stroke-like migraine attacks after radiation therapy," "radiation induced delayed changes," "SMART," "radiation, stroke, migraine", and "radiation, migraine." A total of 47 536 brain MRIs were performed during this period, 9 reports of which contained our search items of interest. The following clinical inclusion criteria were applied to these 9 patients: inpatient adults (>18 years of age) with history of cranial radiation presenting with acute neurologic deficits as primary admission reason who lacked evidence of recurrent or new brain malignancy, stroke, or infectious agents in cerebrospinal fluid. As a result, 3 patients were excluded; the first was thought to have findings of recurrent tumor growth, and the second and third patients had no acute neurological deficits on presentation.
The following information was collected for the 6 remaining patients: demographic data, clinical features, diagnostic findings (including EEG findings), therapeutic interventions, and clinical outcomes. Data were extracted from reviewing clinical charts, video EEG monitoring reports, and MRI brain reports. All 6 patients met the published diagnostic criteria of SMART. 1 All underwent a thorough neurologic workup that excluded a new or recurrent brain malignancy, infection, or stroke. Continuous video EEG monitoring (for a minimum of 48 hours) was performed during their hospital stay. SE was defined as convulsive seizures lasting >5 minutes, or focal seizures with impaired consciousness lasting >10 minutes. 9 The study was approved by the institutional review board.
| RESULTS
| Clinical demographics
Age of presentation was between 29 and 69 years; 10-24 years elapsed from cranial radiation to symptom onset (Table 1) . Both primary brain and metastatic malignancies were represented. Prior to presentation, Patients 1, 2, 3, and 4 had recurrent clinical events that were variably diagnosed as partial seizures, nonepileptic paroxysmal events, transient ischemic attacks, or complex migraines. Patients 1 and 4 had negative prior EEGs (although Patient 4 was still diagnosed clinically with partial seizures), whereas Patients 2 and 3 had not received EEG monitoring before presentation. All 4 patients were on maintenance antiepileptic medications. No patient had a history of SE prior to presentation.
All patients presented with new focal neurologic deficits, including neglect, hemiparesis, numbness on one side, visual field cuts, and aphasia. In addition, patients were found to have mental status change, ranging from mild confusion to stupor. Two patients (2, 6) had witnessed clinical seizure at presentation (Table 3 ). Four patients (1, 2, 5, 6) who all had a history of chronic headaches reported headache with their presentation. Patient 1 had 2 separate presentations marked 1a and 1b.
| Brain imaging
In all patients, MRI of the brain was performed while the patients still showed persistent new neurologic deficits. • Clinical neurological improvement in these patients was seen with antiseizure therapy
• Recognition of SMART as a potential epileptic syndrome allows prompt intervention reported to be unchanged (Table 2 ). There were no radiographic findings of recurrent or new malignancy. Lateralized cortical gyriform enhancement was seen in all patients reported by the neuroradiologist as suggestive of SMART. Five patients had T2 signal abnormality. Three patients had evidence of diffusion restriction, which completely resolved in 2 patients on follow-up (Tables 2 and 4 ). In Patients 2, 3, 4, and 5, subdural fluid collections were found in conjunction with parenchymal abnormalities that were improved (4), stable (2, 3) or resolved (5) on follow-up imaging (Table 4) . Acute radiographic abnormalities resolved completely in follow-up MRIs in Patients 1, 3, 5, and 6, whereas the remainder of patients had partial improvement on follow-up ( (presentation 1b), which were otherwise noted to be remarkably similar in radiographic appearance. Perfusion studies were performed in Patients 1 and 4 and showed an asymmetric periictal hyperperfusion state corresponding to the affected hemisphere ( Figure 1 ).
| Clinical seizures and results of EEG monitoring
Five patients (1b, 2, 3, 4, 6) were found to be in SE. Of these 5, 1 patient (4) had 2 clinical convulsions (convulsive SE) without return to baseline while not connected to EEG; subsequent EEG within the short term showed continued seizure activity in the form of a single prolonged nonconvulsive seizure lasting 14 minutes. The other 4 patients (1b, 2, 3, 6) were in nonconvulsive SE with multiple seizures and persistent mental status change, which improved in parallel with resolution of seizure activity (Tables 3 and 4) . Patients 2 and 6 presented with an initial convulsive seizure. Patient 3 had intermittent clonic jerking and "electric shocks" of the left extremity with worsening mental status. Only Patient 1b had nonmotor seizures correlating with a sudden change in mental status. In Patient 3, the initial 30 minutes of EEG recording showed continuous electrographic seizure activity ( Figure  2) . In another 4 patients (1, 2, 4, and 6), long-term monitoring was needed to capture electrographic seizures. In all 5 patients with SE, EEG showed lateralized seizure activity corresponding to imaging and clinical findings. In only 1 patient (Patient 5), no electrographic seizures were detected after 78 hours of EEG monitoring. In this patient, EEG showed right hemispheric slowing consistent with the MRI abnormalities. In Patient 1's first presentation (1a), no seizures were found; however, in his subsequent presentation (1b), electrographic seizures were found arising from the left hemisphere, correlating with MRI findings.
Administration of antiepileptic drugs (AEDs) was associated with clinical improvement in all 5 patients with seizures. Seizures resolved in all but 1 patient. In this patient (3), the seizure frequency decreased from 12 per hour to 5 per day, and his mental status significantly improved (Table 4) .
| Other studies and treatment
Four patients (1a, 2, 3, 5) had documented fever determined to be of non-central nervous system infectious etiology. These 4 patients were found to have respiratory infections at or shortly after presentation. Lumbar puncture in all patients (except 1b, not performed) were normal. Two patients showed mildly elevated protein level (Table 1) . Cytology was negative in all patients but 1 (not sent in Patient 3). All patients received antiepileptic medications. Patient 4 received corticosteroids (due to a suspicion of autoimmune etiology prior to SMART diagnosis) approximately 1 week after seizures had resolved. Patients 1b and 6 received verapamil, the former shortly after seizure onset and concurrently with antiepileptic medications, and the latter 1 week prior to seizure onset for migraine prophylaxis (verapamil was discontinued 1 day after seizure onset). 
| DISCUSSION
We present a series of 6 consecutive patients diagnosed with SMART who all underwent continuous video EEG monitoring. The clinical courses of 5 patients were remarkable in their presentation of SE; 4 patients were in nonconvulsive SE, whereas the remaining patient was in initial convulsive SE. SMART is generally considered to be a spectrum of migrainelike attacks that may involve reversible hemispheric dysfunction corresponding to MRI changes. 1 Our findings suggest seizures may play a previously underrecognized role in the pathophysiology of SMART. To our knowledge, this is the first case series to demonstrate electrographic status in SMART patients. Although clinical seizures associated with SMART were described as early as 2006, they are thought to be transient, with spontaneous resolution. 1, 3, 4, 10, 11 Clinical SE has only recently been described by Hametner et al. 7 and Jaraba et al. 8 In the 3 patients reported by Jaraba et al., presenting symptoms were headache and negative neurologic symptoms such as hemianopia, aphasia, sensory changes, and hemiparesis, consistent with complicated migraine. In the first patient, these symptoms progressed to right arm clonic seizures. The second patient had visual auras followed by tonic gaze deviation, whereas the last patient had visual auras followed by left homonymous hemianopsia. Similarly, Hametner et al. described a patient presenting with headache, hemiparesis, and altered responsiveness. Although negative neurologic symptoms are more classically associated with migraine, these symptoms, including aphasia, may also be associated with epilepsy. 12 The pathophysiology of SMART syndrome remains intensely debated. Radiation-induced vascular dysfunction may lead to transient, episodic symptoms seen at presentation, and may well explain the radiographic changes seen in SMART. Endothelial dysfunction and vasculopathy similar to that observed in posterior reversible encephalopathy syndrome, 16 leading to a loss of vascular autoregulation, particularly in the posterior cortex, have been postulated to be a possible mechanism. 2-4 A second suggested mechanism is described as neuronal dysfunction induced by radiation. It is thought that a lowered threshold to cortical spreading depression may predispose SMART patients to migraines and focal neurological deficits. 3 In our series, 4 patients presented with headaches, including the 1 patient not found to be in SE. A comorbidity between seizure and migraine has long been recognized. 17 Cortical spreading depression, described as excitatory electrical activity followed by neuronal inhibition and glial activation, has been widely accepted as the mechanism by which migrainous aura occurs. 18 It has been further postulated that migraine-triggered seizures, or migralepsy, classically occurring during such auras, are a result of such hyperexcitability leading to synchronous firing. 19 Recent work with electrocorticographic recordings consistently demonstrates that ictal epileptic discharges and seizures may comanifest with spreading depolarization in patients with acute brain injury, 20,21 a finding supported by in vitro electrophysiological studies. 22 Given common excitatory pathways of migraine and seizure, radiation effects on the trigeminovascular system causing neuronal dysfunction and a reduced threshold to cortical spreading depression may equally reduce the threshold for epileptogenic activity in SMART. [23] [24] [25] Functional imaging studies provide additional insight into the pathophysiology of SMART. Hametner and Jaraba demonstrated focal hypermetabolism and hypoperfusion on positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging, respectively. In our case series, perfusion studies performed in Patients 1 and 4 showed an asymmetric peri-ictal hyperperfusion state corresponding to the affected hemisphere on MRI. The presence of PET hypermetabolism or SPECT hyperperfusion suggests epileptic activity, even if previous authors were not able to show ictal activity on EEG as in our series. 26, 27 Interestingly, SMART patients are thought to have a baseline hypoperfused state, thought to be a direct consequence of radiation. 28 Several studies have supported the finding of relative hyperperfusion during symptomatic episodes. 8, 10, 29 Although radiation-induced vascular dysfunction may appear to cause such hyperperfusion states reported in SMART, it is also plausible that these hyperperfusion states may actually be a consequence of seizure activity. We hypothesize that in patients with SMART, especially when adjunctive imaging such as PET or SPECT supports focal hypermetabolism or hyperperfusion, ongoing epileptiform activity may play an important role in the pathophysiology contributing to the encephalopathy and focal neurological symptoms. Evidence of dual mechanisms of neuronal and vascular dysfunction suggest complex pathophysiologic interactions in SMART, and numerous mechanisms, including cerebral hyperexcitability causing seizures, may result in the distinct clinical findings of these patients. Radiation-induced changes in SMART may place it within the epilepsy-migraine syndromes that include mitochondrial encephalopathies and posttraumatic brain disorders. Although radiation-induced changes are a major component of the SMART etiology, it is yet unknown whether there are additional triggers that provoke symptom onset. Four of our patients (1a, 2, 3, and 5) presented with febrile respiratory infections at, or close to, presentation. Febrile illness may have precipitated acute SMART symptoms, in addition to lowering seizure threshold, although further work is needed to better elucidate the complex pathophysiology that provokes SMART symptoms to appear years, at times decades, after the initial radiation event.
Two unexpected MRI findings were noted. First, subdural fluid collections were noted in 4 of our patients (2, 3, 4, and 5) in conjunction with SMART parenchymal abnormalities. Clinical significance remains unclear, although 1 patient (Patient 5) required surgical drainage due to large size. Notably, this patient demonstrated right lateralized EEG slowing and was the only patient who had no electrographic seizures on long-term monitoring, although clinical improvement was seen with AED initiation. It is possible that overlying fluid may have masked cortical epileptiform activity in this patient. Second, half of our patients (2, 3, and 5) demonstrated diffusion restriction (DR) in conjunction with more typical MRI findings. In at least 2 of our patients (3 and 5), DR findings resolved completely (Patient 2 had a limited follow-up MRI at 15 months), suggestive of a temporal relation to SMART symptoms. Transient DR, thought by some to represent reversible cytotoxic edema in the setting of brain injury, 30 is not a characteristic finding in SMART, although its presence has been noted previously in rare cases. 2, 31 Although its presence may suggest a more severe pathophysiologic variation of SMART, it is uncertain how these findings may be interpreted in the context of seizure activity (as Patient 5 did not have seizures).
Prior observations of the similarity of MRI findings in SMART compared to those commonly observed in ictal and postictal MRI findings in SE 8 have been made, raising the possibility of seizure-induced changes in the brain of SMART patients. Patient 4 in our series had repeated MRIs throughout her clinical course, including a study performed 5 days prior to initial clinical seizure onset that showed no acute change. Subsequent MRI within 24 hours of electrographic seizure activity demonstrated typical hemispheric gyriform enhancement and T2 signal abnormality (Table 1) , suggesting a temporal relation of seizures to MRI changes. MRI changes attributed to SE are thought to vary greatly in appearance, at times focal, multifocal, diffuse, or hemispheric. 32 These changes are typically attributed to transient adenosine triphosphate deficiency and energy failure. MRI changes in SMART, however, appear to uniformly present with hemispheric confluent gray matter changes that do not respect vascular boundaries. 2 It is possible that these consistently extensive hemispheric MRI changes seen in our SMART patients relate to a preexisting postradiation neuronal injury. 33 Alternatively, the preexisting vasculopathy in SMART may explain imaging findings in 2 ways. First, a disrupted blood-brain barrier can lead to gadolinium enhancement. Second, T2 signal changes may represent the insufficient autoregulation and lack of vascular response to hypermetabolic demands during seizure activity. This baseline neuronal or vascular dysfunction may also partially explain the delayed resolution of MRI abnormalities and the prolonged clinical recovery in SMART patients. All 5 patients with SE improved clinically with antiepileptic medications (Table 4) . Verapamil, anecdotally used in SMART patients, and thought to be effective in cases of hemiplegic migraine, 34 was used in Patient 1b concurrently with antiepileptic medication. In this case, it is not possible to determine whether one particular therapy had a greater contribution to clinical improvement. Verapamil was initiated as migraine prophylaxis in Patient 6 at presentation, 1 week prior to seizure onset. There was no clinical improvement, and verapamil was discontinued shortly after seizures occurred. Efficacy of calcium channel antagonists remain debated in SMART, partly due to uncertain etiology of the syndrome. Similarly, because Patient 4 had already shown clinical improvement and seizure resolution when intravenous corticosteroids were introduced, it is difficult to ascertain the role of autoimmune therapy in SMART patients.
One major limitation of our study is the small sample size. Given the rare prevalence of SMART in our patient population, identification of cases was optimized with the presence of MRI findings in conjunction with a history of cranial radiation and acute neurological deficits. It was also not possible to ascertain whether the involved radiologists were blinded to the clinical case, given the retrospective nature of the study. This is a retrospective study reporting 6 patients with SMART, 5 of whom were found to have SE. Four patients were in nonconvulsive SE, whereas the fifth presented initially in convulsive SE. Despite our small sample size, our findings indicate that although the acronym of SMART describes a primarily migrainous spectrum of symptoms, it is a misnomer that fails to emphasize the presence of a treatable epileptic process. It is worthwhile to note that the majority of SE in our case series was nonconvulsive. Only 1 patient presented with SE on initial 30-minute EEG; all others required long-term EEG monitoring to confirm seizures or SE. Timely recognition of SMART as a potential epileptic syndrome predisposing patients to nonconvulsive SE allow prompt intervention, minimizing symptom duration and time to recovery. Continuous EEG should be considered an essential diagnostic tool. Additional studies, including perfusion images and PET, may be considered for further diagnostic purposes.
